Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

A rough earnings report raised troubling questions about UHG’s future, and so did the resignation of CEO Andrew Witty.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (BIT:1HALO) from Market Perform to Underperform. There are 1,095 funds or institutions ...

Fintel reports that on May 7, 2025, Leerink Partners upgraded their outlook for Amylyx Pharmaceuticals (NasdaqGS:AMLX) from Market Perform to Outperform. As of May 7, 2025, the average one-year ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...